PDCD1 and esophageal squamous cell carcinoma: The pooled FPS and OS rates from the combination immunotherapy group were significantly higher than those from the PD‐1 inhibitor monotherapy group in immunotherapy‐naive ESCC patients (Figure 5C,D).